Phase 1 Results Support Losmapimod as FSHD Treatment

Phase 1 Results Support Losmapimod as FSHD Treatment
4.7
(9)

Final results of a Phase 1 clinical trial support the safety of losmapimod and suggest its effectiveness as a treatment for facioscapulohumeral muscular dystrophy (FSHD).

The data, “Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability and Target Engagement,” were presented by Michelle Mellion, MD, at a virtual session of the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. Mellion is the senior medical director at Fulcrum Therapeutics, the company developing losmapimod.

More than 90% of cases of FSHD are caused by mutations that lead to hyperactivity of the gene DUX4. Losmapimod is given orally to selectively block the p38 alpha and p38 beta proteins that regulate DUX4.

The primary goal of the Phase 1 trial was to determine the safety and  tolerability of losmapimod. The trial included three groups. In the first, eight of 10 healthy volunteers were given a 7.5 mg dose of the treatment, followed by a washout period, then a 15 mg dose. The other two participants received a placebo.

In the second group, 15 people with FSHD were assigned randomly to either losmapimod or placebo. The therapy was given at doses of either 7.5 mg or 15 mg, taken twice a day for 14 days.

The third group had five participants with FSHD, who were given 15 mg losmapimod twice per day.

Safety and pharmacology results were similar in healthy volunteers and individuals with FSHD. The overall safety profile of losmapimod was consistent with previous data from more than 3,500 healthy volunteers and patients treated with this therapy across other indications, Fulcrum said in a press release. No serious adverse events (SAEs) were reported.

Analyses of samples of the participants’ blood and muscle tissue suggested the losmapimod was engaging its target in a dose-dependent manner. Treatment doses in blood and muscle also were higher with the greater dose (15 mg).

“Losmapimod was well tolerated with no SAEs reported and achieved dose-dependent exposure [levels] in plasma and muscle at concentrations predicted by pre-clinical models demonstrating efficacy by reducing DUX4 activity,” the investigators wrote.

These data also support the selection of a twice-daily 15 mg dose of losmapimod, which is being used in an ongoing Phase 2b clinical trial called ReDUX4 (NCT04003974), investigating the therapy’s safety and effectiveness.

ReDUX4 completed enrollment last month, with results expected in early 2021. Participants in ReDUX4 can continue on the therapy in a Phase 2 extension study (NCT04264442).

As a potential treatment for FSHD, losmapimod recently was designated an orphan drug by the U.S. Food and Drug Administration, which gives Fulcrum financial incentives and other forms of support to successfully conduct clinical development.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 42
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • trials in age of Covid-19
  • real-world data in clinical trials
  • muscle cells and proteins
  • casimersen and FDA review

How useful was this post?

Click on a star to rate it!

Average rating 4.7 / 5. Vote count: 9

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?